Zacks Investment Research lowered shares of Asterias Biotherapeutics (NYSEAMERICAN:AST) from a hold rating to a sell rating in a report released on Friday.
According to Zacks, “Asterias Biotherapeutics, Inc. is a biotechnology company. It is focused on the field of regenerative medicine. The Company’s technologies center on stem cells capable of becoming all of the cell types in the human body, a property called pluripotency. It develops therapies based on pluripotent stem cells to treat diseases or injuries in a variety of medical fields, with an initial focus on the therapeutic areas of neurology and oncology. Asterias Biotherapeutics, Inc. is based in Menlo Park, California. “
Separately, HC Wainwright set a $11.00 target price on shares of Asterias Biotherapeutics and gave the stock a buy rating in a research note on Monday, January 8th. Two equities research analysts have rated the stock with a sell rating and three have issued a buy rating to the company’s stock. Asterias Biotherapeutics presently has a consensus rating of Hold and a consensus price target of $8.94.
Asterias Biotherapeutics (NYSEAMERICAN:AST) last released its quarterly earnings data on Tuesday, November 14th. The biotechnology company reported ($0.15) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.15). Asterias Biotherapeutics had a negative net margin of 403.38% and a negative return on equity of 79.80%.
About Asterias Biotherapeutics
Asterias Biotherapeutics, Inc is a biotechnology company. The Company is engaged in developing and commercializing therapies in the fields of cell therapy and regenerative medicine. The Company has over two technology platforms. The first is an immunotherapy platform to teach cancer patients’ immune systems to attack their tumors.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Asterias Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Asterias Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.